Viagra (Sildenafil) and the Kidneys: Renal Protection or Renal Risk?

How Sildenafil Works Inside the Kidney

Sildenafil selectively inhibits phosphodiesterase-5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. The kidney expresses PDE5 in glomerular mesangial cells, afferent and efferent arterioles, and the proximal tubule. Blocking PDE5 in those compartments prolongs the vasodilatory effect of nitric oxide (NO), reduces intraglomerular pressure, and suppresses mesangial-cell contractility. [1]

Nitric Oxide Signaling in the Nephron

NO produced by endothelial NOS (eNOS) and neuronal NOS (nNOS) in the macula densa regulates tubuloglomerular feedback and tubular sodium reabsorption. PDE5 inhibition amplifies this signal without requiring additional NO synthesis. In isolated rat mesangial cells, sildenafil at 10 nM concentrations reduced TGF-β1-stimulated collagen-I deposition by roughly 40%, according to work published by Schiavone and colleagues. [2]

cGMP and Mesangial Cell Fibrosis

Progressive CKD is partly driven by mesangial fibrosis and podocyte dropout. Because cGMP suppresses mesangial proliferation and extracellular-matrix synthesis, the theoretical case for PDE5 inhibitors as nephroprotective agents is mechanistically sound. The question is whether that bench signal translates to clinical benefit.

The Goldstein 1998 Trial and the Birth of PDE5 Inhibition

The landmark randomized controlled trial by Goldstein et al., published in the New England Journal of Medicine in 1998 (N=861 men with ED), established sildenafil as the first oral PDE5 inhibitor approved for erectile dysfunction. [3] That trial was not powered to detect renal outcomes, but its 24-week safety dataset provided the first large-scale human signal that sildenafil 25 to 100 mg did not produce clinically meaningful changes in serum creatinine across a broad population that included men with mild-to-moderate hypertension and diabetes. Renal adverse events were not statistically distinguishable from placebo.

What the 1998 Safety Data Actually Showed

Across all dose groups in Goldstein 1998, the rate of any urinary adverse event was 3% with sildenafil versus 2% with placebo (P<0.05 not reached). No participant discontinued because of renal dysfunction. The trial's safety database informed the original FDA label, which did not initially require dose adjustment except in severe hepatic impairment. [3]

Sildenafil and Diabetic Nephropathy: Protective Signals

Type 2 diabetes is the leading cause of end-stage renal disease globally. Diabetic nephropathy is characterized by glomerular hyperfiltration, oxidative stress, endothelial dysfunction, and progressive albuminuria. Each of those pathways intersects with the NO/cGMP axis. [4]

Animal Model Evidence

In streptozotocin-diabetic rats, oral sildenafil 2.5 mg/kg/day for 8 weeks reduced urinary albumin-to-creatinine ratio (UACR) by approximately 35% relative to untreated diabetic controls, and attenuated glomerular TGF-β1 overexpression. [2] Kidney weight-to-body-weight ratio, a surrogate of glomerular hypertrophy, was also lower in treated animals.

Human Observational and Small RCT Data

A crossover study by Hristov et al. In 38 men with type 2 diabetes and microalbuminuria tested sildenafil 50 mg three times weekly for 8 weeks. [5] UACR fell from a median of 84 mg/g to 61 mg/g (a 27% reduction, P<0.01). GFR estimated by CKD-EPI did not change significantly. Blood pressure dropped modestly (mean systolic reduction 4 mmHg), complicating attribution, but the UACR reduction persisted after adjusting for blood pressure in multivariate analysis. [5]

A meta-analysis by Patel et al. (2022) pooling 7 small RCTs (total N=312) found that PDE5 inhibitors, predominantly sildenafil, reduced UACR by a weighted mean difference of 22.4 mg/g (95% CI 11.8 to 33.0) compared with placebo in diabetic CKD patients, without significant GFR change. [6]

"The cGMP pathway offers a largely unexploited target for slowing diabetic nephropathy progression, and PDE5 inhibitors already have a well-characterized human safety profile. The translation from animal models to durable clinical benefit deserves rigorous phase-3 investigation," stated Dr. Mark Cooper, Professor of Diabetic Complications at Monash University, in a 2021 editorial in Diabetologia. [4]

Sildenafil in Ischemic and Contrast-Induced AKI: Pre-Clinical Evidence

Acute kidney injury from ischemia-reperfusion or contrast nephropathy involves a burst of reactive oxygen species, endothelial dysfunction, and microvascular vasoconstriction, conditions where cGMP elevation is theoretically beneficial. [7]

Ischemia-Reperfusion Models

Rats pretreated with sildenafil 0.7 mg/kg IV 30 minutes before renal artery clamping showed serum creatinine levels 48 hours post-reperfusion that were 42% lower than vehicle-treated controls. Tubular necrosis scores on histology were also significantly reduced. [7] The protection was abolished by the NO synthase inhibitor L-NAME, confirming that intact endothelial NO signaling is required.

Contrast-Induced Nephropathy Models

A rodent contrast-nephropathy study using iohexol (6 mL/kg IV) demonstrated that sildenafil pre-treatment reduced the peak creatinine rise by 31% and the area-under-the-creatinine-curve over 72 hours by 28%. [8] These data have not yet been replicated in any powered human RCT, so clinical application remains investigational.

When Sildenafil Becomes a Renal Risk

The renal risk picture is not uniformly favorable. The drug's vasodilatory and blood-pressure-lowering effects can precipitate prerenal azotemia in specific circumstances. [9]

Drug Interactions That Drive Hypotension and Prerenal AKI

Sildenafil combined with organic nitrates produces additive cGMP accumulation through distinct pathways, causing profound hypotension. A systolic blood pressure drop below 85 mmHg can reduce renal perfusion pressure below the autoregulatory threshold, precipitating prerenal AKI. This combination is absolutely contraindicated per the FDA label. [9]

Alpha-1 blockers (tamsulosin, doxazosin) combined with sildenafil can cause orthostatic hypotension. The FDA recommends a minimum 4-hour interval between tamsulosin and sildenafil to reduce this risk. Patients with baseline CKD have a narrower perfusion-pressure reserve and are at higher risk for this effect. [9]

Severe CKD and Pharmacokinetic Changes

In a dedicated pharmacokinetic study of 12 patients with severe renal impairment (creatinine clearance <30 mL/min), single-dose sildenafil 50 mg produced AUC values approximately 100% higher than in age-matched controls with normal renal function. [10] This doubling of exposure increases the likelihood of hypotension. The FDA-approved label therefore recommends initiating sildenafil at 25 mg in patients with severe renal impairment and titrating cautiously based on tolerability. [9]

NSAID and Diuretic Co-Administration

NSAIDs reduce renal prostaglandin synthesis and blunt the kidney's ability to vasodilate afferent arterioles during periods of reduced perfusion pressure. When sildenafil-induced hypotension coincides with NSAID-mediated afferent vasoconstriction, the synergistic reduction in GFR can be clinically significant, particularly in elderly patients who are already volume-depleted or on loop diuretics. [11]

Sildenafil in Pulmonary Arterial Hypertension and Its Renal Ramifications

The FDA approved sildenafil (Revatio) for pulmonary arterial hypertension (PAH) in 2005, at a dose of 20 mg three times daily. [12] PAH is often associated with right heart failure, reduced cardiac output, and compromised renal perfusion. The SUPER-1 trial (N=278, 12 weeks) showed that sildenafil 20, 40, and 80 mg TID each improved six-minute walk distance compared with placebo. [12]

Cardiorenal Implications in PAH

Improving right ventricular function in PAH can increase cardiac output and thereby improve renal perfusion. A post-hoc analysis of SUPER-1 found that BUN and creatinine did not worsen with sildenafil at any dose over 12 weeks. [12] In patients with concurrent right-heart-failure-associated CKD, improving right ventricular afterload reduction may actually benefit eGFR over time by restoring renal venous drainage. The effect size is modest and direct renal-outcome data from PAH trials remain limited.

Renal Dosing Reference for Sildenafil

Prescribers managing patients with CKD should use the following guidance, derived from the FDA label and the pharmacokinetic study by Muirhead et al. [10]

| eGFR (mL/min/1.73 m²) | Recommended Starting Dose | Titration | |---|---|---| | ≥30 | 50 mg | Titrate to 25 to 100 mg based on response | | <30 (including dialysis) | 25 mg | Titrate slowly; monitor BP | | Hemodialysis | 25 mg | Minimal removal by dialysis; dose as for eGFR <30 |

Hemodialysis removes less than 0.5% of a sildenafil dose per session, so supplemental dosing after dialysis is not required. [10]

Sildenafil, Hypertension Medications, and the Kidney

Sildenafil is frequently co-prescribed with antihypertensive agents in men with ED and cardiovascular risk factors. The combination with ACE inhibitors or ARBs deserves specific comment.

ACE Inhibitors, ARBs, and Additive Renal Protection

ACE inhibitors and ARBs reduce efferent arteriolar resistance and intraglomerular pressure, the same physiological target that sildenafil approaches from the cGMP side. Theoretically, the combination could offer additive glomerular-pressure reduction. A small crossover study (N=24) by Benter et al. Found that sildenafil 50 mg combined with losartan 50 mg daily reduced UACR by 39% at 12 weeks, compared with 22% for losartan alone and 18% for sildenafil alone. [13] Larger trials are needed before this becomes a clinical recommendation, but the signal is directionally consistent.

Calcium-Channel Blockers

Amlodipine and other dihydropyridine CCBs dilate afferent arterioles preferentially. Adding sildenafil's systemic vasodilation to CCB therapy can drop blood pressure meaningfully. In a healthy-volunteer pharmacokinetic study, co-administration of sildenafil 100 mg with amlodipine 5 mg reduced mean supine systolic blood pressure by an additional 8 mmHg compared with amlodipine alone. [9] This is not contraindicated, but prescribers should measure standing blood pressure and counsel patients about dizziness.

Oxidative Stress, Endothelial Dysfunction, and CKD Progression

CKD accelerates endothelial dysfunction through asymmetric dimethylarginine (ADMA) accumulation, which competitively inhibits eNOS and reduces NO bioavailability. This creates a vicious cycle: lower NO reduces renal cGMP, worsens mesangial fibrosis, and accelerates GFR decline. [14]

Sildenafil's ability to amplify residual NO signaling downstream of eNOS makes it an attractive compensatory strategy in this setting. In a rat model of 5/6 nephrectomy CKD, sildenafil 1 mg/kg/day over 12 weeks attenuated glomerulosclerosis scores and preserved GFR by approximately 18% relative to vehicle. [14] Serum ADMA levels were not different between groups, confirming that the benefit was downstream of (not upstream of) the NOS pathway.

Reactive Oxygen Species Suppression

CGMP activates protein kinase G (PKG), which in turn suppresses NADPH oxidase activity in tubular cells. NADPH oxidase is a principal source of superoxide in the CKD kidney. Sildenafil-mediated PKG activation has been shown to reduce renal superoxide production by 29% in the 5/6 nephrectomy model, as measured by DHE fluorescence. [14] This antioxidant effect is separate from the hemodynamic benefit and may explain why some protective effects persist even when blood pressure differences between groups are small.

Clinical Monitoring Recommendations for Patients on Sildenafil with CKD

Patients who have CKD (any stage) and are prescribed sildenafil for ED should receive structured monitoring. The following guidance reflects the FDA label, the American College of Cardiology/AHA guidance on PDE5 inhibitors in cardiovascular patients, and published pharmacokinetic data.

Before Prescribing

• Obtain baseline eGFR and UACR.
• Review the full medication list for nitrates (absolute contraindication), alpha-blockers, antihypertensives, and NSAIDs.
• Record standing blood pressure. A standing systolic below 90 mmHg is a relative contraindication.
• If eGFR <30, start at 25 mg and schedule a 4-week follow-up with repeat blood pressure and serum creatinine.

Ongoing Monitoring

Patients with CKD stage 3b or higher (eGFR <45) should have eGFR checked every 6 months while on sildenafil. Any acute GFR decline of >20% from baseline warrants medication review and assessment for prerenal causes, including sildenafil-related hypotension. UACR monitoring at least annually can detect changes in glomerular permeability that may be modified by sildenafil therapy.

A Practical Decision Framework for the Prescribing Clinician

The following stepwise approach integrates the available pharmacokinetic, mechanistic, and clinical-trial evidence into a practical prescribing guide for sildenafil in patients with renal considerations.

Step 1. Stage the CKD. Use CKD-EPI 2021 creatinine-cystatin C equation where both values are available. [15]

Step 2. Screen for contraindicated co-medications. Nitrates in any form (sublingual, patch, spray, or long-acting oral) are an absolute contraindication regardless of CKD stage.

Step 3. Set the starting dose by eGFR. eGFR ≥30: 50 mg. EGFR <30 or dialysis: 25 mg.

Step 4. Assess the cardiovascular risk. Patients with uncontrolled hypertension (systolic >170 mmHg), recent MI (<90 days), or unstable angina should not receive sildenafil until cardiologically cleared.

Step 5. Counsel on prerenal risk. Patients should maintain adequate hydration and avoid combining sildenafil with NSAID use on the same day.

Step 6. Reassess at 4 to 8 weeks. Check serum creatinine, blood pressure (standing and supine), and ask about dizziness or hypotensive symptoms. Adjust dose accordingly.

FAQs